Abstract 2957: CD127 is expressed by acute lymphoblastic leukemias and is efficiently targeted by the IL7R-antagonist OSE-127 through macrophage-mediated antibody dependent phagocytosis
Irène Baccelli(OSE Immunotherapeutics (France)), Nicolas Poirier(OSE Immunotherapeutics (France)), Frédérique Corallo(OSE Immunotherapeutics (France)), Julien Taurelle(OSE Immunotherapeutics (France)), Anna Laqua(University Hospital Schleswig-Holstein), Gunnar Cario, Anna Dietterle(Christian-Albrechts-Universität zu Kiel), Dorothee Winterberg(Christian-Albrechts-Universität zu Kiel), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Martin Schrappe(Medizinische Hochschule Hannover), Lennart Lenk(University Hospital Schleswig-Holstein), Monika Brüggemann(University Hospital Schleswig-Holstein), Fotini Vogiatzi(Christian-Albrechts-Universität zu Kiel), Simon Raffel(Heidelberg University), Beat Bornhäuser(University Children's Hospital Zurich), Emma Narbeburu(OSE Immunotherapeutics (France)), Denis M. Schewe(Klinik und Poliklinik für Kinder- und Jugendmedizin)
Cited by 1
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2000|599